UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of ~~July~~August 2009

Commission File Number: 0-29350

Vasogen Inc.

(Translation of registrant’s name into English)

4 Robert Speck Parkway, 15th Floor, Mississauga, Ontario, L4Z 1S1

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x

Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1). _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o

No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VASOGEN INC.



	By:	/s/ Graham Neil
	Name:	Graham Neil
	Title:	Vice-President, Finance and
		Chief Financial Officer

Date: ~~July~~August 1417, 2009

EXHIBIT LIST

Exhibit		Description
99.1		~~Financial~~News ~~Statements~~Release ~~and~~dated ~~Notes~~August to17, ~~Consolidated~~2009 ~~Financial~~- ~~Statements~~Vasogen ~~for~~Receives ~~the~~NASDAQ ~~period~~Notification ~~ended~~Related ~~May~~to ~~31,~~Minimum ~~2009~~Bid Price
99.2		~~Management’s~~News ~~Discussion~~Release dated August 17, 2009 Vasogen and ~~Analysis~~IntelliPharmaCeutics ~~for~~to ~~the~~Combine ~~period~~to ~~ended~~Create ~~May~~Publicly-traded ~~31,~~Specialty ~~2009~~Pharmaceutical Company
99.3		Forms 52-109F2 CEO/CFO Certification of Interim Filings

Filing Compare · VASOGEN INC